A comprehensive state-level analysis reveals where adult obesity is highest across the United States, projecting that nearly half of adults could be living with obesity by 2035, with stark disparities by...
Primary care clinicians routinely counsel patients whose eating patterns reflect diverse cultural traditions. This resource offers practical, evidence-based strategies for supporting balanced nutrition...
A new cost-effectiveness modeling study evaluates whether coronary artery calcium scoring can refine cardiovascular risk stratification and help identify obese patients most likely to derive clinical and...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
